Phibro Animal Health (PAHC) Projected to Announce Quarterly Earnings on Wednesday

Phibro Animal Health (NASDAQ:PAHC) is projected to release its Q1 2027 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $0.7830 per share and revenue of $382.42 million for the quarter. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. Individuals can check the company’s upcoming Q1 2027 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:00 AM ET.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, August 26th. The company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.14. Phibro Animal Health had a net margin of 6.57% and a return on equity of 37.86%. The firm had revenue of $396.75 million during the quarter, compared to analyst estimates of $381.18 million. On average, analysts expect Phibro Animal Health to post $3.49 EPS for the current fiscal year and $3.81 EPS for the next fiscal year.

Phibro Animal Health Price Performance

Shares of Phibro Animal Health stock opened at $38.74 on Tuesday. Phibro Animal Health has a 52-week low of $28.25 and a 52-week high of $60.08. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of 11.80 and a beta of 0.42. The company has a fifty day moving average of $37.04 and a 200-day moving average of $41.11. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.27 and a current ratio of 2.96.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Phibro Animal Health in a research report on Friday, September 11th. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $47.67.

About Phibro Animal Health

Phibro Animal Health Corporation develops, manufactures and sells products designed to support the health, nutrition and productivity of food-producing animals. Its offerings include animal health products, vaccines, medicated feed additives, nutritional specialties and performance products used in livestock, poultry and aquaculture.

The company’s products are intended to help prevent and manage disease, improve animal well-being and support efficient food production. Phibro serves producers, veterinarians, feed manufacturers and distributors through a portfolio that includes pharmaceuticals, vaccines, mineral and nutritional supplements, and other feed and water solutions.

Phibro Animal Health markets its products internationally across a broad range of geographic regions, including North America, Latin America, Europe, Asia-Pacific and other global markets.